| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000027398 |
| Receipt No. | R000031399 |
| Official scientific title of the study | The beneficial effect of a functional food containing Lactobacillus on human gastrointestinal function : double blind, placebo-controlled study |
| Date of disclosure of the study information | 2017/12/28 |
| Last modified on | 2017/12/28 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | The beneficial effect of a functional food containing Lactobacillus on human gastrointestinal function : double blind, placebo-controlled study | |
| Title of the study (Brief title) | The beneficial effect of a functional food containing Lactobacillus on human gastrointestinal function | |
| Region |
|
|
| Condition | |||
| Condition | Individuals with a tendency for constipation | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | In order to investigate the efficacy of the intake of the functional food on individuals with constipation |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | defecation frequency, stool output |
| Key secondary outcomes | defecation days, fecal condition |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | intake of a test food containing with lactobacillus for 2 consecutive weeks | |
| Interventions/Control_2 | intake of a placebo for 2 consecutive weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) Males and females from 20 to 64 years of age
(2) Subjects with a tendency for constipation at three to five times of defecation per week |
|||
| Key exclusion criteria | (1) Subjects who routinely takes foods or medicines containing of Lactobacillus
(2) Subjects who routinely takes foods or medicines containing of Bacillus subtilis var. natto (3) Subjects who routinely takes foods or medicines affecting the test result (4) Subjects having diseases affecting bowel movement or a history of these diseases (5) Subjects having possibilities for emerging allergy related to the study (6) Subjects who has asthma or the possibility of asthma (7) Subjects who is employed on a pre-dawn shift or on night duty more than 2 times (8) Subjects who is planned to go overseas (9) Subjects who has treatment or a history of serious disease (10) Subjects who has treatment of disease (11) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination on screening test (12) Subjects who have participated in other clinical study within the last one month prior to the current study or are planned to participate in other clinical study after informed consent for the current study (13) Subjects who are planned to become pregnant after informed consent for the current study or are pregnant or lactating (14) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire (15) Subjects judged as unsuitable for the study by the investigator for other reasons |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Takehisa Kumagai |
| Organization | KAMEDA SEIKA CO., LTD. |
| Division name | RICE RESEARCH INSTITUTE |
| Address | 3-1-1 Kameda Kogyo Danchi, Konan-ku, Niigata City, Niigata |
| TEL | 025-382-8879 |
| t_kumagai@sk.kameda.co.jp | |
| Public contact | |
| Name of contact person | Shingo Yamamichi |
| Organization | TTC Co.,Ltd. |
| Division name | Clinical Research Planning Department |
| Address | 1-20-2, Ebisunishi, Shibuya-ku, Tokyo |
| TEL | 03-5459-5329 |
| Homepage URL | |
| s.yamamichi@ttc-tokyo.co.jp | |
| Sponsor | |
| Institute | TTC Co.,Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | KAMEDA SEIKA CO., LTD. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031399 |